US Next-Generation Sequencing Services Market Report and Forecast 2026-2034

Study Period

2021-2034

Market (2026)

USD 3.5 Billion

Market (2034)

USD 14.46 Billion

CAGR

19.40%

Major Markets Players

Illumina, Inc., Thermo Fisher Scientific Inc., Eurofins Scientific SE, PerkinElmer, Inc., QIAGEN and Others

*Note: Partial List Randomly Ordered

US Next-Generation Sequencing Services Market Key Takeaways

US Next-Generation Sequencing Services Market Insights & Analysis

The US Next-Generation Sequencing Services Market is anticipated to register a 19.40% CAGR during 2026–2034. The market size was valued at USD 3.5 billion in 2026 and is projected to reach USD 14.46 billion by 2034. Sustained growth is driven by expanding clinical adoption of whole-genome and whole-exome sequencing, rising demand for oncology genomic profiling, and increasing integration of sequencing-as-a-service platforms for rare disease diagnosis. Federal investments exceeding USD 3.6 billion annually through the National Institutes of Health genomics programs continue reinforcing infrastructure development, while the All of Us Research Program has already enrolled over one million participants, generating unprecedented sequencing demand.

The US market benefits from one of the world's most advanced genomics research ecosystems, with academic medical centers, contract research organizations, and specialty genomics laboratories actively expanding sequencing capacity. Increasing multi-omics workflow adoption - combining genomics, transcriptomics, epigenomics, and proteomics - is extending service complexity and average revenue per sample. Biopharma companies are deploying next-generation sequencing for companion diagnostic development and regulatory submissions at an accelerating pace, creating durable, high-volume service contracts with leading genomics service providers across the country.

US Next-Generation Sequencing Services Market Dynamics

The US Next-Generation Sequencing Services Market continues expanding across research, clinical, and translational genomics applications as sequencing costs decline and turnaround times improve. Increasing biopharma pipeline activity, expanding hospital-based genomics programs, and growing demand for reproductive genetic testing are reinforcing sustained service provider revenue growth. Regulatory clarity around clinical sequencing reimbursement further strengthens the market's long-term commercial foundation.

Key Market Driver: Federal Genomics Funding Strengthens Demand

National Institutes of Health genomics research funding has consistently exceeded USD 3.6 billion annually, directly supporting sequencing service procurement across universities, academic medical centers, and federally funded research institutions. Programs including the All of Us Research Program, Cancer Moonshot initiative, and Undiagnosed Diseases Network have generated multi-year sequencing service contracts. This federal commitment has reinforced whole-genome sequencing service adoption across US research institutions, enabling service providers to invest in capacity expansion, automation, and bioinformatics capabilities while maintaining stable utilization rates independent of private sector cycles.

Major Industry Challenge: Clinical Data Interoperability Barriers

Despite rapid clinical adoption, the US Next-Generation Sequencing Services Market faces significant friction from fragmented electronic health record ecosystems, inconsistent variant interpretation standards, and complex HIPAA-compliant data transfer requirements across institutions. Sequencing service providers managing data pipelines for hospital clients must navigate multiple compliance frameworks, proprietary data formats, and variable bioinformatics infrastructure maturity. These barriers extend project timelines, increase operational costs, and create reimbursement uncertainty for clinical laboratory improvement amendments-certified sequencing laboratories operating across multi-state healthcare systems.

Emerging Trend Shaping Outlook: Long-Read Sequencing Service Expansion

Pacific Biosciences HiFi sequencing and Oxford Nanopore long-read platforms are fundamentally reshaping the US sequencing service landscape by enabling complete structural variant detection, phased genome assembly, and methylation profiling within a single workflow. Leading service providers are rapidly integrating long-read offerings alongside short-read platforms to address structural genomics, repeat expansion disorders, and complex oncology profiling use cases. This transition is expanding long-read sequencing and epigenomics service portfolios beyond traditional short-read applications, increasing per-project service value and opening entirely new clinical and translational revenue streams for specialized genomics laboratories.

US Next-Generation Sequencing Services Market Segment-wise Analysis

The US Next-Generation Sequencing Services Market exhibits distinct service demand patterns across workflow stages and end-use categories. Pre-sequencing, sequencing, and data analysis services each command differentiated pricing and turnaround structures, while end-use demand reflects the growing divergence between research-driven and clinically oriented sequencing applications.

By Workflow

• Pre-sequencing Service
• Sequencing Service
• Data Analysis Service

Sequencing Service accounts for the largest workflow share at an estimated 48% of total market revenue, anchored by demand for whole-genome, whole-exome, RNA sequencing, and targeted panel services across biopharma, academic, and clinical clients. Illumina short-read platforms dominate installed capacity at US service providers, enabling high-throughput sample processing at competitive per-base costs. Standardized library preparation kits, sequencing reagent contracts, and volume-based pricing agreements with pharmaceutical clients reinforce the sequencing service segment's revenue stability and market leadership.

Pre-sequencing Service is experiencing renewed investment as service providers standardize nucleic acid extraction, library preparation, and quality control workflows to support multi-omics and long-read sequencing compatibility. Data Analysis Service represents the fastest-growing workflow segment, expanding beyond basic variant calling to include structural variant annotation, polygenic risk scoring, single-cell transcriptomics analysis, and AI-assisted clinical report generation. The integration of cloud-based genomic data analysis platforms is enabling service providers to offer scalable bioinformatics pipelines, reduce turnaround time for large cohort projects, and build recurring revenue through software-as-a-service bioinformatics subscriptions targeting biopharma and hospital clients.

By End-Use

• Universities & Other Research Entities
• Hospitals & Clinics
• Pharma & Biotech Entities
• Other End-uses

Pharma and biotech entities represent the dominant end-use segment with an estimated 42% market share, driven by expanding genomics-enabled drug discovery pipelines, companion diagnostic development programs, and regulatory-grade biomarker validation studies requiring certified sequencing service providers. Large pharmaceutical companies are increasingly outsourcing sequencing workflows to specialized service providers to access accredited laboratory infrastructure, validated bioinformatics pipelines, and rapid scalability without capital-intensive instrument procurement. Multi-year service agreements with global biopharma clients provide sequencing service providers with predictable revenue and utilization rates that support continued capacity investments.

Universities and other research entities constitute a critical demand segment, accessing sequencing services through NIH-funded grants, institutional genomics core facilities, and collaborative research consortia. Hospitals and clinics represent the fastest-growing end-use category as oncology panel testing, pharmacogenomics, and rare disease diagnostics transition from academic research into routine clinical workflows. The expansion of Medicare and commercial insurance reimbursement for clinical next-generation sequencing panel testing in oncology is accelerating hospital adoption, while direct-to-consumer genetic testing companies and reproductive health service providers contribute incremental volume across Other End-uses.

Regional Projection of US Next-Generation Sequencing Services Market

The US Next-Generation Sequencing Services Market demonstrates significant regional concentration, with the Northeast and West regions anchoring national revenue generation due to dense academic medical center networks, biopharmaceutical industry clusters, and established genomics research infrastructure. Southern and Midwestern markets are accelerating adoption driven by regional health system expansion and emerging biotech ecosystems.